GKV Capital Management Co. Inc. Takes $145,000 Position in Novo Nordisk A/S (NYSE:NVO)

GKV Capital Management Co. Inc. acquired a new position in Novo Nordisk A/S (NYSE:NVO) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 1,684 shares of the company’s stock, valued at approximately $145,000.

A number of other large investors have also recently bought and sold shares of NVO. M. Kulyk & Associates LLC grew its stake in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company’s stock worth $274,000 after buying an additional 119 shares during the last quarter. Center for Financial Planning Inc. increased its holdings in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Tradewinds Capital Management LLC raised its position in Novo Nordisk A/S by 2.6% in the fourth quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company’s stock valued at $429,000 after purchasing an additional 124 shares during the last quarter. Exencial Wealth Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 0.5% during the fourth quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company’s stock valued at $1,987,000 after purchasing an additional 124 shares in the last quarter. Finally, Indie Asset Partners LLC increased its stake in shares of Novo Nordisk A/S by 4.2% in the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company’s stock valued at $269,000 after buying an additional 126 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 2.5 %

Shares of Novo Nordisk A/S stock opened at $62.88 on Thursday. The stock’s 50-day moving average is $76.55 and its 200 day moving average is $92.55. Novo Nordisk A/S has a one year low of $59.32 and a one year high of $148.15. The firm has a market cap of $282.18 billion, a price-to-earnings ratio of 19.11, a PEG ratio of 0.90 and a beta of 0.61. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were paid a $0.7874 dividend. This represents a dividend yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend was Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.54%.

Analysts Set New Price Targets

Several research firms recently commented on NVO. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BNP Paribas initiated coverage on Novo Nordisk A/S in a research note on Tuesday. They issued an “underperform” rating for the company. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.